SCHEMBL470552

SCHEMBL470552

CC(C)(C)OC(=O)N[C@@H]1CCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.68

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 9/20 0.68
CYP2C9 P11712 1/20 0.68
CTSK P43235 2/20 0.61
CA1 P00915 1/20 0.59
CA2 P00918 1/20 0.59
EPHX1 P07099 1/20 0.58
USP30 Q70CQ3 5/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8296190 1.00 HSD11B1 (0.68) HSD11B1CYP2C9CTSKCA1CA2
SCHEMBL5822208 1.00 HSD11B1 (0.68) HSD11B1CYP2C9CTSKCA1CA2
SCHEMBL1782544 0.92 HSD11B1 (0.60) HSD11B1CYP2C9CTSKCA1CA2
SCHEMBL2037731 0.92 HSD11B1 (0.60) HSD11B1CYP2C9CTSKCA1CA2
SCHEMBL22680068 0.92 HSD11B1 (0.60) HSD11B1CYP2C9CTSKCA1CA2
SCHEMBL17545919 0.91 CA1 (0.71) HSD11B1CYP2C9CTSKCA1CA2
SCHEMBL18926997 0.90 EPHX1 (0.70) HSD11B1CYP2C9CTSKCA1CA2
SCHEMBL15084717 0.90 HSD11B1 (0.57) HSD11B1CYP2C9CTSKCA1CA2
SCHEMBL15084767 0.90 HSD11B1 (0.57) HSD11B1CYP2C9CTSKCA1CA2
SCHEMBL655025 0.88 HSD11B1 (0.62) HSD11B1CYP2C9CTSKCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3640248-B1 AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) 2023-08-23 EP disclosed
US-11352352-B2 Aminopyrimidine compound, preparation method therefor and use thereof Beijing Adamadle Biotechnology Limited Liability Company (CN) 2022-06-07 US disclosed
CN-113121575-A (substituted phenyl) (substituted pyrimidine) amino derivative and preparation method and pharmaceutical application thereof 四川海思科制药有限公司 2021-07-16 CN disclosed
EP-3313832-B1 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME (US) 2021-02-24 EP disclosed
US-20200087296-A1 AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Beijing Adamadle Biotechnology Limited Liability Company (CN) 2020-03-19 US disclosed
CN-106458969-A (substituted phenyl) (substituted pyrimidine) amino derivative and preparation method and pharmaceutical application thereof 四川海思科制药有限公司 2017-02-22 CN disclosed
WO-2016029839-A1 (SUBSTITUTED PHENYL) (SUBSTITUTED PYRIMIDINE) AMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICATION USE 四川海思科制药有限公司 2016-03-03 WO disclosed
WO-2016029839-A1 (SUBSTITUTED PHENYL) (SUBSTITUTED PYRIMIDINE) AMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICATION USE 四川海思科制药有限公司 2016-03-03 WO disclosed
WO-2011147951-A1 CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS PROSIDION LIMITED (GB) 2011-12-01 WO disclosed
EP-1689752-B1 PYRAZOLOPYRIMIDINES PFIZER LTD (GB) 2008-02-27 EP disclosed
US-20070270412-A1 NOVEL PHARMACEUTICALS PFIZER INC 2007-11-22 US disclosed
US-20070270412-A1 NOVEL PHARMACEUTICALS PFIZER INC 2007-11-22 US disclosed
US-7262192-B2 Substituted pyrazolo[4,3-d]pyrimidines and their use as PDE-5 inhibitors PFIZER INC. (US) 2007-08-28 US disclosed
US-7262192-B2 Substituted pyrazolo[4,3-d]pyrimidines and their use as PDE-5 inhibitors PFIZER INC. (US) 2007-08-28 US disclosed
US-20070105877-A1 Pyrazolopyrimidines PFIZER INC 2007-05-10 US disclosed
US-20070105877-A1 Pyrazolopyrimidines PFIZER INC 2007-05-10 US disclosed
CN-1780841-A 5,7-diaminopyrazolo[4,3-d]pyrimidines useful in the traetment of hypertension PFIZER LTD (GB) 2006-05-31 CN disclosed
WO-2005049617-A1 PYRAZOLOPYRIMIDINES PFIZER LIMITED (GB) 2005-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105877-A1 Pyrazolopyrimidines DPYD, CYP2D6, TPMT HSD11B1 1641/4885CYP2C9 37/4885CTSK 3171/4885
US-20070270412-A1 NOVEL PHARMACEUTICALS ABCB11, PCSK9, SLC10A1 HSD11B1 491/4885CYP2C9 76/4885CTSK 146/4885
US-20200087296-A1 AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF WEE1, WEE2, EGFR HSD11B1 2776/4885CYP2C9 592/4885CTSK 3545/4885
US-11352352-B2 Aminopyrimidine compound, preparation method therefor and use thereof WEE1, WEE2, EGFR HSD11B1 2776/4885CYP2C9 592/4885CTSK 3545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.